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Adult stem cells are a “reservoir” of potential cells at various stages of 
development and can be used for the restoration and regeneration of damaged tissues and 
organs. Under proper conditions, stem cells may differentiate into specialized tissues and 
organs. These unique features make them a promising tool for studies on therapy for 
diseases such as chronic liver disease, heart attack, spinal injuries, stroke, diabetes 
mellitus and others. 
The liver is one target for which the development of stem cell-based therapy is of 
great significance. Even though an injured liver is highly regenerative, many debilitating 
diseases lead to hepatocyte dysfunction and organ failure. Treatments such as resection 
are not applied because of too little remaining liver function. Liver transplantation is the 
only effective treatment for severe liver injuries. However, because of organ rejection and 
the limited number of donors, alternative therapeutic approaches are needed. Stem cells 
could offer a potentially unlimited and minimally invasive source of cells for hepatocyte 
replacement and liver regeneration. 
Mesenchymal stem cells (MSCs) have been found in bone marrow, amniotic fluid, 
placenta, adipose tissue, umbilical cord blood, and many fetal tissues and organs. Even 
though isolated from different tissues, they share a similar surface marker profile and 
differentiation ability. 
The hepatogenic differentiation capacity of MSCs has been confirmed in many 
independent studies. The possibility for their future application in the therapy of liver 
diseases is very promising. MSCs can be easily obtained from a patient’s own tissues, 
isolated ex vivo, expanded, differentiated toward hepatocytes, and transplanted back into 
the patient in form of either undifferentiated MSCs or MSC-derived hepatocytes. In the 
future, together with the development of tissue engineering technologies, MSC-derived 
hepatocytes may be transplanted back to the patients in the form of three dimensional 
culture, or liver devices. Such a possibility sidesteps the limits regarding ethical issues 
and immunocompatibility problems. Importantly, MSCs represent an advantageous cell 
type for allogenic transplantation as well, since they are immuno-privileged with low 
MHC I (HLA I) and no MHC II (HLA II) expression, therefore reducing the risk of 
allogenic transplant rejection. Currently, attention is being given to adipose tissue (AT) as 
a source of MSCs for regenerative medicine. AT-MSCs are very similar to bone marrow 
(BM) - MSCs with respect to surface markers profile and differentiation potential. From 
adipose tissue, a sufficient number of stem cells for stem cell-based therapy may be 
obtained without invasiveness or damage to a patient’s health. 
The studies are a tightly connected trilogy. The content of it describes 
characterization of AT-MSCs (Part I), their in vitro hepatogenic differentiation 
potentiality, including functionality and cytochrome P-450 activity (Part II), and finally, 
their therapeutic potential after transplantation into immunodeficient mice with liver 
injury (Part III). All of the studies have important impact for future establishment of the 
therapy for liver diseases. 
Part I: Characterization of AT-MSCs. 
AT-MSCs were isolated from subcutaneous adipose tissue of six gastric cancers 
undergoing gastrectomy in the International Medical Center of Japan. The AT-MSCs 
were characterized regarding their surface marker profile by using RT-PCR analyses, 
immunofluorostaining and flow cytometry. They were sorted by using CD105 conjugated 
magnetic beads (MACS). CD105 (endoglin) is one of several candidate mesenchymal stem 
cell markers, and is a receptor for the pleiotropic TGF-β superfamily. An elevated 
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potential capacity of CD105+ AT-MSCs has been confirmed by differentiation toward 
mesoderm lineages such as adipo-, chondro-, and osteo-genic. 
Part II: In vitro hepatogenic differentiation of CD105+ AT-MSCs. Functional analyses of 
CD105+ AT-MSC-derived hepatocyte-like cells. 
Maintenance of a primary human hepatocyte function in vitro is difficult if not 
nearly impossible. Therefore, an alternative source is needed. AT-MSC-derived 
hepatocyte-like cells can offer an unlimited source of cells for hepatocyte replacement and 
studies on drug metabolism and toxicology. 
The hepatogenic differentiation of CD105+ AT-MSCs was established based on our 
previous studies on mouse ES cells. It takes five weeks, and is composed of a 
3-step-induction system on collagen type I coated dishes: HGF + FGF1 + FGF4 (Step 1), 
OsM + DEX (Step2), and hepatocyte culture medium alone (Step 3). Hepatocyte-specific 
characteristics of CD105+ AT-MSC-derived hepatocyte-like cells were evaluated by 
morphological changes, by the presence of hepatocyte-specific markers (albumin, 
alpha-fetoprotein, tryptophan 2,3-dioxygenase, hepatocyte nuclear factor-4alpha, and 
others), by immunochemistry (CYP3A4, transthyretin, cytokeratin 18), and by 
biochemical assays (LDL uptake, glycogen storage ability, albumin production ability, 
ammonia detoxification ability). Additionally, the metabolizing activity of CD105+ 
AT-MSC-derived hepatocyte-like cells was examined. The results include the expression 
(RT-PCR, western blot, microarray) and the activity (LC-MS/MS) of selected xenobiotic 
metabolizing enzymes: cytochrome P450s (CYPs) in CD105+ AT-MSC-derived 
hepatocyte-like cells. The activity of six types of CYP (1A2, 2B6, 2C9, 2C19, 2D6, and 3A) 
in CD105+ AT-MSC-derived hepatocyte-like cells was detected and compared with the 
activity of primary human hepatocytes. 
CD105+ AT-MSC-derived hepatocyte-like cells exhibited morphology and functions 
similar to normal human hepatocytes. In summary, using specific growth factors and 
collagen type I coating, we generated in vitro functional hepatocyte-like cells from 
CD105+ AT-MSCs. The ability of CD105+ AT-MSC-derived hepatocyte-like cells to 
metabolize xenobiotics makes them an attractive tool for further studies on new drug 
metabolism and toxicity. 
Part III: Modification of hepatocyte induction system. In vivo therapeutic potential of 
unfractionated AT-MSCs and AT-MSC-derived hepatocyte-like cells after transplantation 
into mice with liver injury. 
This last part concerns in vivo transplantation. Our study was performed in order 
to evaluate the possibility of future clinical usage of AT-MSCs in the treatment of liver 
diseases. Future safety issues for patients require a special approach, such as shortening 
as much possible ex vivo modifications and a hepatogenic differentiation strategy. For 
that, MACS sorting was not applied and the hepatogenic induction strategy was 
shortened and modified. At present, it takes two weeks, and it is enriched in 
pre-treatment with Activin A and FGF4 (one of the cues secreted by septum transversum 
mesenchyme (STM) and cardiogenic mesoderm at the early stage of endoderm 
development in vivo). Additionally, nicotinamide, insulin-transferrin-selenium, and 
DMSO were added. After two weeks of this modified induction strategy, AT-MSCs 
differentiated into functional hepatocyte-like cells. For cell transplantation, 
undifferentiated AT-MSCs and AT-MSC-derived hepatocyte-like cells were harvested from 
the dishes and transplanted into mice with liver injury. 
Twenty-four hours post CCl4 injury, undifferentiated AT-MSCs (n=6) (Group III) 
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or AT-MSC-derived hepatocyte-like cells (n=8) (Group IV) were transplanted 
intravenously. The results were compared with two controls, mice with liver injury and no 
cell transplantation (n=3) (Group II), and mice without injury and no cell transplantation 
(n=3) (Group I). Twenty-four hours after cell transplantation, the mice were sacrificed. 
The livers were fixed and serial sections were stained with anti-human specific albumin 
antibodies. The presence of human-specific albumin cells was detected after 
transplantation with AT-MSC-derived hepatocyte-like cells (Group IV). Blood plasma was 
evaluated for biochemical parameters, such as ammonia concentration and markers of 
liver injury: GPT (glutamic-pyruvic transaminase), GOT (glutamic-oxaloacetic 
transaminase) and UA (uric acid). The results show significant improvement of those 
factors after transplantation of AT-MSC-derived hepatocyte-like cells (Group IV). 
Noteworthy is that mice transplanted with undifferentiated AT-MSCs (Group III) 
surprisingly also revealed improvement of biochemical parameters. Additionally, we 
found few HLA-1-positive cells after transplantation of AT-MSCs (Group III). A 
histological examination revealed that AT-MSC-derived hepatocyte-like cells (Group IV) 
significantly and AT-MSCs (Group III) not significantly improved the morphology of host 
mice hepatocytes. The livers of mice transplanted with either AT-MSCs (Group III) or 
AT-MSC-derived hepatocyte-like cells (Group IV), revealed less vacuolar degeneration 
caused by dilatation of mitochondria and rough endoplasmic reticulum. 
We postulate that the involvement of undifferentiated AT-MSCs may be due to 
their pleiotrophic contribution through their indirect activity. Thus, we analyzed the 
production of cytokines/growth factors by undifferentiated AT-MSCs, and compared it 
with bone marrow-derived mesenchymal stem cells (BM-MSCs) and normal human 
dermal fibroblasts (NHDFs). A higher secretion of IL-1RA, IL-6, IL-8, G-CSF, GM-CSF, 
MCP-1, NGF, and HGF by AT-MSCs, as opposed to BM-MSCs and NHDFs was detected. 
An in vitro cytokine/growth factor assay demonstrated a higher production of bioactive 
factors in AT-MSCs than in BM-MSCs and therefore possibly higher trophic activity of 
AT-MSCs versus BM-MSCs.  
The usage of autologous undifferentiated AT-MSCs would be an extremely cheap, 
fast and hopeful strategy for patients with severe liver diseases. It would eliminate a long 
waiting time, risk of rejection, and the additional high costs of ex vivo manipulations. The 
safety issues, however, including post-transplantation tumorigenesis, should be carefully 
evaluated. 
reasonable. 
Conclusions: 
AT-MSCs reveal a capacity to differentiate in vitro into functional hepatocyte-like 
cells, and therefore may be used in future studies on drug metabolism and toxicology. 
Generated in vitro hepatocyte-like cells as well as undifferentiated AT-MSCs per se have 
therapeutic capacity and improve liver function and host hepatocyte-morphology. The 
usage of autologous AT-MSCs would be an extremely cheap, fast and hopeful strategy for 
patients with severe liver diseases. The safety issues, however, including 
post-transplantation tumorigenesis, should be carefully evaluated. 
We propose that AT-MSCs, as a highly available source of stem cells, which can be 
obtained without invasiveness from a patient’s own adipose tissue, can be an ideal tool for 
the future establishment of a new, alternative and sufficient stem cell-based therapy for 
liver diseases. 
 
